Core Insights - NuGen Medical Devices Inc. is developing a next-generation needle-free injection system aimed at improving drug delivery technology, protected under international patent WO2021206553 [1][2] - The new system integrates a sterile internal insulin cartridge into the needle-free autoinjector, eliminating the need for external connectors and reducing dosing errors and contamination risks [2][6] - The innovation is expected to enhance patient experience for those requiring daily injections, positioning it as a competitor to pen-based injectors [3] Technical Highlights - The internal cartridge integration streamlines the injection process by removing the need for external adaptors and manual filling [6] - A backflow control mechanism is included to ensure precise and safe insulin delivery, addressing unique challenges of jet injection [6] - Improved usability is a focus, simplifying operation for patients and caregivers, which is anticipated to reduce training time and improve compliance [6] Future Milestones - NuGen plans to begin clinical investigations using its currently approved needle-free platform, allowing for parallel development of the new cartridge-based system [6] - The company aims to produce working prototypes within six months to showcase the technology and conduct usability studies [6] - Full tooling investment for scaled manufacturing and commercialization is expected to commence in early 2026 [6] Company Overview - NuGen Medical Devices specializes in next-generation needle-free devices for subcutaneous drug delivery, with its flagship InsuJet™ system approved in 42 countries [5]

Core Viewpoint - AVITA Medical, Inc. is actively engaging with investors through participation in three upcoming investor conferences in September 2025, highlighting its commitment to investor relations and market presence [1][2]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery [4]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [4]. - In addition to RECELL, AVITA holds exclusive rights in the U.S. for manufacturing and distributing PermeaDerm and Cohealyx™, both of which are innovative wound care products [4]. International Market Presence - The RECELL System is approved for a variety of applications in international markets, including Australia, Europe, and Japan, demonstrating its global reach and regulatory compliance [5]. Upcoming Events - AVITA Medical will host investor meetings at the Cantor Global Healthcare Conference on September 4, 2025, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025 [8]. - A live audio webcast of the Morgan Stanley fireside chat featuring CEO Jim Corbett will be available for replay for 90 days on the company's Investor Relations website [3].

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST). ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, R ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Align Technology, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Align Technology reported total revenues of approximately $1.01 billion for Q2 2025, which was below both consensus estimates and the company's own guidance [3]. - The company lowered its revenue guidance for Q3 and full-year growth expectations, attributing this to economic uncertainty and reduced demand for its products [3]. - Following the announcement, Align's stock price fell by $74.56 per share, or 36.63%, closing at $129.01 per share on July 31, 2025 [3]. Legal Investigation - The investigation by Pomerantz LLP is aimed at determining if Align and its executives engaged in any fraudulent activities that may have misled investors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4].

A private equity firm’s bid to combine the two biggest makers of medical-device coatings would harm competition for life-saving technologies, the Federal Trade Commission said at the start of a trial to block the deal https://t.co/GSbQiEZOvi ...

Key Takeaways Microbot gained a U.S. patent expanding LIBERTY's applications with modular tool-receiver units.The new patent increases Microbot's U.S. market opportunity from 2.5M to over 6M procedures.Shares have risen 7.1% after the news, with year-to-date gains of 195.5% against industry decline.Microbot Medical Inc. (MBOT) has been granted a new U.S. patent that broadens the potential applications of its LIBERTY Endovascular Robotic System. The patent covers a modular design that allows interchangeable ...

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong fourth-quarter fiscal 2025 performance and ongoing studies [1][6][10] - The company's shares have seen a slight decline of 0.3% year-to-date, contrasting with a 7% decline in the industry and an 8.8% increase in the S&P 500 [1][2] Company Performance - AngioDynamics has a market capitalization of $358.8 million and projects a 50% growth over the next year, with earnings surpassing the Zacks Consensus Estimate in the last four quarters, averaging a surprise of 72.58% [2][3] - The fourth-quarter fiscal 2025 results showed a narrower adjusted loss per share and revenues exceeding expectations, indicating strong execution across both operating segments [11] Product and Market Dynamics - The NanoKnife product, which received FDA clearance and Breakthrough Device Designation, generated total revenues of $24.5 million in fiscal 2025, with fourth-quarter revenues of $7.2 million reflecting growth in disposable sales despite softer capital placements [3][4] - Recurring disposable sales grew by 9.6% for the year, providing a reliable revenue stream to offset variability in system placements [3] Clinical and Product Development - AngioDynamics is advancing a broad pipeline of clinical studies, including the AMBITION trial for Auryon and the RECOVER-AV trial for AlphaVac, aimed at enhancing its market position [7][8] - The NanoKnife's PRESERVE prostate trial has met primary endpoints, paving the way for reimbursement catalysts starting in 2026 [8] Financial Outlook - The company anticipates gross margins in the range of 53.5% to 55.5% for fiscal 2026, with adjusted EBITDA projected between $3.0 million and $8.0 million [13] - However, there has been a negative estimate revision trend for fiscal 2026, with the consensus estimate for loss per share expanding from 6 cents to 30 cents [14]

Core Insights - Medtronic (NYSE: MDT) reported its financial results before the market opened on Tuesday, showing a relatively solid performance despite a negative market reaction [1] - The analysis suggests that the reported numbers appear satisfactory upon closer examination, indicating potential undervaluation [1] Financial Performance - The financial results released by Medtronic indicate a stable performance, although specific figures and metrics were not detailed in the provided content [1] Market Reaction - Despite the solid financial results, the market's immediate reaction was negative, which may present an opportunity for investors who can identify value in the company's fundamentals [1]

Key Takeaways Teleflex Incorporated (TFX) recently announced the launch of the Barrigel rectal spacer in Japan, effective immediately following regulatory approval, insurance coverage acceptance and the issuance of appropriate use criteria by Japanese academic societies. Barrigel's commercialization in Japan marks a milestone in the company's global expansion strategy. Barrigel rectal spacer is the first and only hyaluronic rectal spacer that separates the prostate from the rectum to protect the latter duri ...

Milestones underscore Resmed's leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features R ...